ARDS (Moderate or Severe)
11
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
Clinical Trial of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
The PRE-VAIL Study
Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome
STimulation to Activate RespIration
PEEP-induced Effects on Respiratory dRivE and EFfort
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes
FAPI PET/CT to Detect Fibroblast Activity in Non-resolving ARDS
Role of Elastic Power in Acute Respiratory Distress Syndrome
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)